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Summary
Background Mental disorders can adversely affect HIV treatment outcomes and survival. Data are scarce on premature 
deaths in people with mental disorders in HIV-positive populations, particularly in low-income and middle-income 
countries. In this study, we quantified excess mortality associated with mental disorders in HIV-positive people in 
South Africa, adjusting for HIV treatment outcomes.
Methods For this cohort study, we analysed routinely collected data on HIV-positive adults receiving antiretroviral 
therapy (ART) in Cape Town, South Africa between Jan 1, 2004, to Dec 31, 2017. Data from three ART programmes 
were linked with routine medical records on mental health treatment from Jan 1, 2010, to Dec 31, 2017, and 
mortality surveillance data from the South African National Population Register up to Dec 31, 2017. People living 
with HIV aged 15 years or older who initiated ART at a programme site were eligible for analysis. We followed up 
patients from ART initiation or Jan 1, 2010, whichever occurred later, to transfer, death, or Dec 31, 2017. Patients 
were considered as having a history of mental illness if they had ever received psychiatric medication or been 
hospitalised for a mental disorder. We calculated adjusted hazard ratios (aHRs) with 95% CIs for associations 
between history of mental illness, mortality, and HIV treatment outcomes (retention in care with viral load 
suppression [VLS; viral load <1000 copies per mL], retention in care with non-suppressed viral load [NVL; viral load 
≥1000 copies per mL], and loss to follow-up [LTFU; >180 days late for a clinic visit at closure of the database]) using 
Cox proportional hazard regression and multistate models.
Results 58 664 patients were followed up for a median of 4·3 years (IQR 2·1–6·4), 2927 (5·0%) of whom had a history 
of mental illness. After adjustment for age, sex, treatment programme, and year of ART initiation, history of mental 
illness was associated with increased risk of mortality from all causes (aHR 2·98 [95% CI 2·69–3·30]), natural causes 
(3·00 [2·69–3·36]), and unnatural causes (2·10 [1·27–3·49]), compared with no history of mental illness. Risk of all-
cause mortality in people with a history of mental illness remained increased in multivariable analysis adjusted for 
age, sex, treatment programme, year of ART initiation, CD4 count and WHO clinical stage at ART initiation, retention 
in HIV care with or without VLS, and LTFU (2·73 [2·46–3·02]). In our multistate model, adjusted for age, sex, year of 
ART initiation, cumulative time with NVL, and WHO clinical stage and CD4 cell count at ART initiation, rates of 
excess all-cause mortality in people with history of mental illness were greatest in patients retained in care with VLS 
(aHR 3·43 [95% CI 2·83–4·15]), followed by patients retained in care with NVL (2·74 [2·32–3·24]), and smallest in 
those LTFU (2·12 [1·78–2·53]). History of mental illness was also associated with increased risk of HIV viral rebound 
(transitioning from VLS to NVL; 1·50 [1·32–1·69]) and LTFU in people with VLS (1·19 [1·06–1·34]).
Interpretation Mental illness was associated with substantial excess mortality in HIV-positive adults in Cape Town. 
Excess mortality among people with a history of mental illness occurred independently of HIV treatment success. 
Interventions to reduce excess mortality should address the complex physical and mental health-care needs of people 
living with HIV and mental illness.
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Introduction
In 2017, mental illness was a leading cause of disease 
burden in Africa. The South African Stress and Health 
study, which collected national population data between 
2003, and 2004, showed that mental disorders affected 
one in three adults in South Africa during their lifetime.1 
Anxiety, depression, and substance use disorders were 
the most common mental disorders, each affecting more 
than 10% of the population at least once during life.1 
Severe mental disorders including schizophrenia, 
psychosis, and bipolar disorder are not as common, 
usually occurring in less than 2% of the population.
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For 2017 Global Burden of 
Disease estimates see 
https://vizhub.healthdata.org/
gbd-compare/ 
People with mental disorders have higher mortality 
than the general population. Excess mortality in mental 
disorders has been well documented for high-income 
countries.2 A meta-analysis of 148 studies found that the 
pooled relative risk of all-cause mortality in people with 
mental disorders was two times higher than that in 
individuals without a mental disorder or the general 
population.2 However, most studies included in the meta-
analysis were from Europe or North America. Only six 
studies were from low-income and middle-income 
countries, of which only two were from Africa. Both 
studies were done in Ethiopia and showed standardised 
mortality ratios of about 4 in people with major 
depression and 6 in people with schizophrenia.3,4
Although mental disorders are prevalent in people 
living with HIV5 and associated with poor adherence 
to life-saving antiretroviral therapy,6 data are scarce 
on premature deaths in people with mental disorders 
in HIV-positive populations, and mostly restricted to 
high-income countries.7–9 One study in Tanzania showed 
that depressive symptoms at ART initiation were 
associated with a two times higher risk of mortality in 
women living with HIV.10 In the current study, we aimed 
to evaluate excess mortality associated with mental 
disorders in people living with HIV. We quantified excess 
mortality in people with a history of mental illness (ie, 
people who had ever been hospitalised for a mental 
disorder or received psychiatric medications) among 
HIV-positive adults who had initiated ART in three HIV 
programmes in Cape Town, South Africa, and examined 
associations between a history of mental illness and HIV 
treatment outcomes.
Methods
Study design
In this cohort study, we analysed routinely collected data 
on HIV-positive adults receiving ART in South Africa. We 
linked data from three ART programmes in Cape Town to 
data on mental health treatment in Western Cape 
province and national mortality surveillance data. ART 
programme data covering the period from Jan 1, 2004, to 
Dec 31, 2017, were provided by the International 
Epidemiology Database to Evaluate AIDS (IeDEA) 
Southern Africa collaboration.11 Mental health records 
covering the period from Jan 1, 2010 (the start of electronic 
collection of records), to Dec 31, 2017, were provided by 
the Western Cape Provincial Health Data Centre.12 This 
service links patient information from several routine 
health information systems, including hospital discharge 
summaries (with International Classification of Diseases, 
10th Revision [ICD-10] diagnoses) and pharmacy records, 
via a unique identifier. All ART programmes participating 
in IeDEA have ethics approval to examine long-term 
outcomes of patients at their facilities through linkage to 
other datasets, and to contribute de-identified data to the 
IeDEA Data Centre. The Western Cape Department of 
Health approved the linkage of ART and mental health 
records. The Human Research Ethics Committee of the 
University of Cape Town, South Africa, and the Cantonal 
Ethics Committee of the Canton of Bern, Switzerland, 
granted permission for analysis of the linked database.
Treatment programmes and patients
Gugulethu Community Health Clinic (CHC), Tygerberg 
Academic Hospital, and the Khayelitsha ART programme, 
Research in context
Evidence before this study
We searched PubMed for reports published in any language 
between Jan 1, 2000, and Aug 1, 2019, with the search terms 
(“excess mortality” OR “premature mortality”) AND (“mental 
illness” OR “mental disorder” OR “depression” OR “anxiety” OR 
“bipolar” OR “psychotic” OR “schizophrenia” OR “substance use” 
OR “alcohol use” OR “trauma” OR “post-traumatic stress”) in 
the title or abstract. Excess mortality in people with mental 
disorders is well documented for high-income countries, 
but data are scarce for low-income and middle-income 
countries and for HIV-positive populations. Additionally, 
the Global Burden of Disease Study does not capture mortality 
attributable to mental disorders in its disability-adjusted 
life-year or years of life lost metrics.
Added value of this study
Our study is one of a few to quantify mortality associated with 
mental illness in HIV-positive populations of low-income and 
middle-income countries and, to our knowledge, the first to do 
so in South Africa, where the HIV-positive population accounts 
for 20% of all cases globally (2018 UNAIDS estimate). 
We analysed a large observational dataset after integrating 
longitudinal data on antiretroviral therapy (ART), mental 
health treatment, and mortality surveillance data on almost 
60 000 people receiving HIV care in public-sector ART 
programmes in Cape Town. The risk of all-cause mortality was 
around 3-times higher in people with a history of mental illness 
than in individuals without. Although history of mental illness 
was associated with decreased retention on ART and decreased 
viral load suppression, our study showed that excess mortality 
in people with mental illness occurred independently of HIV 
treatment success.
Implications of all the available evidence
Our study shows that excess mortality in people with mental 
disorders is an urgent public health problem in settings with a 
high prevalence of HIV. Substantial investments in the 
development, evaluation, and implementation of interventions 
are needed to close the mortality gap for people with mental 
illness. Interventions should go beyond supporting adherence 
to ART to address the complex physical and mental health-care 
needs of people living with HIV and mental illness.
For more on the IeDEA Southern 
Africa see https://www.iedea-sa.
org/
For the Western Cape Provincial 
Health Data Centre see 
https://www.westerncape.gov.
za/general-publication/
provincial-health-data-centre
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all situated in Cape Town, provide public HIV treatment 
according to national guidelines.13 Gugulethu CHC and 
the Khayelitsha ART programme provide primary care 
to the townships of Gugulethu and Khayelitsha, while 
Tygerberg Academic Hospital is a tertiary care, referral 
hospital that generally manages patients with severe 
illness. In the Western Cape province, primary care 
facilities are the first point of care for individuals with both 
common mental disorders and stable, severe mental 
disorders. Individuals with common and severe mental 
disorders requiring either admission or specialised 
services are referred to secondary and tertiary care facilities. 
For our study, people living with HIV aged 15 years or 
older at ART initiation, who had initiated ART at 
Gugulethu CHC, Tygerberg Academic Hospital, or one of 
the health centres of the Khayelitsha ART programme 
(Khayelitsha [Site B] CHC, Michael Mapongwana CHC, 
and Nolungile CHC) were eligible for analysis.
Procedures
We followed up patients from ART initiation or 
Jan 1, 2010, whichever occurred later, to transfer, death, 
IeDEA database closure (Dec 31, 2017), or the end of their 
tenth year on ART. Mortality was documented by the 
ART programmes, which we updated by linking ART 
records to mortality surveillance data from the South 
African National Population Register11,12 up to Dec 31, 2017. 
The National Population Register classified the under-
lying cause of death as unnatural (ICD-10 codes V01–Y99) 
or natural (death due to natural disease per the ICD-10). 
We defined HIV treatment outcomes as retention in care 
with viral load suppression (VLS; viral load <1000 copies 
per mL), retention in care with non-suppressed viral load 
(NVL; viral load ≥1000 copies per mL), and loss to follow-
up (LTFU; >180 days late for a clinic visit at closure of 
the IeDEA database. Patients who were not LTFU, 
deceased, or transferred to a different ART programme 
(censored on transfer) were classified as retained in care. 
Viral rebound was defined as transitioning from VLS to 
NVL. Patients without a viral load measurement at ART 
initiation were initially classified as NVL. HIV treatment 
outcomes were updated whenever the treatment status of 
a patient changed. We assessed the WHO clinical stage 
and CD4 cell count of patients at initiation of ART. Patient 
age was assessed at the beginning of each year. On 
each programme, HIV RNA viral load was measured 
4–6 months after ART initiation, 12 months after ART 
initiation, and annually thereafter, as per national and 
provincial guidelines.13 The year of ART initiation was 
categorised as 2004–07, 2008–11, 2012–14, and 2015–17, 
with years grouped according to ART guideline periods.
Our primary exposure was history of mental illness. We 
classified patients as having a history of mental illness 
if they had ever received psychiatric medication (anti-
psychotics [WHO Anatomical Therapeutic Chemical  code 
N05A], anxiolytics [N05B], hypnotics and sedatives [N05C], 
antidepressants [N06A], or psychostimulants [N06B]) or 
had ever been admitted to hospital for a mental disorder 
(ICD-10 codes F00–F99) or to a psychiatric ward or facility. 
Reason for hospitalisation was classified according to 
the final diagnosis recorded in hospital discharge sum-
maries. Reasons for hospitalisation were substance use 
dis order (ICD-10 diagnoses F10–F19), psychotic disorder 
(F20–F29), affective disorder (F30–F39), and anxiety 
and related disorders (F40–F48). The remaining ICD code 
categories were grouped together as unspecified (F99) or 
as other (F00–F09, F49–F98). We classified pharmacy 
records according to the Anatomical Therapeutic Chemical 
classification system, as antipsychotic (code N05A), 
anxiolytic (N05B), anti depressant (N06A), or other 
psychiatric medication (N05 or N06).
Statistical analysis
We calculated hazard ratios (HRs) and cause-specific 
HRs with 95% CIs for factors associated with excess 
mortality from all causes, natural causes, and unnatural 
causes in people with a history of mental illness using 
univariable Cox proportional hazard models. History of 
mental illness was defined as a time-varying binary 
variable. Patients were considered unaffected by mental 
illness (unexposed) until they had received their first 
mental health treatment; thereafter, patients were 
considered to be exposed. We subsequently examined 
excess mortality in people with a history of mental 
illness in three adjusted multivariable Cox proportional 
hazard models. Model 1 adjusted for age as a time-
varying covariate (15–24 years, 25–34 years, 35–44 years, 
45–54 years, 55–64 years, and ≥65 years), sex, treatment 
programme, and year of ART initiation. Model 2 adjusted 
for all variables included in model 1, and CD4 cell count 
(missing, <100 cells per µL, 100–199 cells per µL, 
200–349 cells per µL, 350–499 cells per µL, and ≥500 cells 
per µL according to WHO thresholds) and WHO clinical 
stage (stage 1, 2, 3, 4, or missing) at ART initiation. 
Model 3 adjusted for all variables included in model 2, 
and HIV treatment outcome as a time-varying covariate 
(retained in care with VLS, retained in care with NVL, 
and LTFU). We did a post-hoc sensitivity analysis using 
alternative definitions of mental illness. In this analysis, 
we con sidered patients to be affected by mental illness 
(exposed) for 1, 2, 3, 4, and 5 years after mental health 
treatment (ie, dispensing of psychiatric medication or 
hospital admis sion for mental disorder), and as unex-
posed thereafter. Patients who never received mental 
health treatment were considered unexposed. We 
calculated aHRs and 95% CIs for associations between 
each of the five exposure variables and all-cause mortality 
using multi variable Cox proportional hazards models 
adjusted for model 2 covariates.
Additionally, we examined excess all-cause mortality in 
people with a history of mental illness according to HIV 
treatment outcomes using a multistate model.14,15 The 
model allowed for transitions between three states 
representing HIV treatment outcomes (retained in care 
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with NVL [state 1], retained in care with VLS [state 2], and 
LTFU [state 3]). From each of these states, patients could 
transition to death (state 4). We used Cox proportional 
hazard models with stratified non-parametric baseline 
hazards to estimate transition probabilities and cause-
specific aHRs and 95% CIs for associations between 
exposure variables and transition rates for each transition 
in the multistate model.15 Multistate models were 
adjusted for age, sex, WHO clinical stage and CD4 cell 
count at ART initiation, year of ART initiation, cumulative 
time with NVL before entering a state, and treatment 
programme. We plotted transition probabilities (expres-
sed as percentage) describing the chances of patients 
with and without a history of mental illness of being in 
each of the four states of the multistate model during 
10 years on ART. We used this multistate model to do a 
prespecified subgroup analysis, in patients who had 
received antipsychotics, antidepressants, or anxiolytics; 
and in patients who had received an ICD-10 diagnosis for 
substance use disorder, psychotic disorder, affective 
disorder, or anxiety disorder. Post-hoc subgroup analyses 
were done in patients who had been hospitalised for 
any mental disorder; in patients who had never been 
hospitalised for a mental disorder but had received 
psychiatric medication; in patients who received mental 
health treatment (ie, psychiatric medication or hospitali-
sation for a mental disorder) during ART; and in patients 
who received mental health treatment before but not 
during ART. In the analysis of patients who had received 
antipsychotics, antidepressants, or anxiolytics, patients 
without a history of use of psychiatric medication were 
the reference group. The reference group in all other 
subgroup analyses was people without a history of 
mental illness. We assessed the proportional hazards 
assumption using Schoenfeld residuals and visual 
inspection of log-log plots. All Cox models were adjusted 
for treatment programme by stratificaton of the baseline 
hazard function because this covariate did not satisfy the 
proportional hazards assumption. We included dummy 
variables to handle missing covariate data. Data were 
managed and analysed with Stata (version 15), R software, 
and the R package mstate.15
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
10 587 patients from Gugulethu, 44 240 from Khayelitsha, 
and 3837 from Tygerberg were followed up for a median 
duration of 4·3 years (IQR 2·1–6·4). Of 58 664 patients, 
2927 (5·0%) had a history of mental illness. 41 453 (70·7%) 
patients were women. The median age at the start of 
follow-up was 33 years (IQR 28–40). 4010 patients (6·8%) 
died during follow-up, of whom 3139 (78·3%) died from 
a natural cause, 216 (5·4%) from an unnatural cause, 
and 655 (16·3%) from an unknown cause (table 1). 
Of 2927 patients with a history of mental illness, 
2565 (87·6%) had received psychiatric medication (of 
whom, 1561 [60·9%] had received antipsychotics) and 
923 (31·5%) had been hospitalised for a mental disorder 
(table 2).
Figure 1 compares the probability of HIV treatment 
outcomes and all-cause mortality within our multistate 
model in patients with and without a history of mental 
illness over 10 years on ART. Among patients with a 
history of mental illness, at 10 years after ART initiation, 
the probability of death was 32·0% (95% CI 28·9–35·1). 
The probabilities of LTFU, retention in care with VLS, 
and retention in care with NVL were 34·0% (30·8–37·1), 
28·9% (26·2–31·7), and 5·1% (3·5–6·7), respectively 
(figure 1A, appendix p 1). Among patients with no history 
of mental illness, at 10 years after ART initiation, the 
probabilities of death, LTFU, retention with VLS, and 
retention with NVL were 13·4% (12·9–13·9), 45·3% 
(44·6–46·0), 38·0% (37·4–38·7), and 3·2% (2·9–3·5), 
respectively (figure 1B, appendix p 1). Transition 
probabilities of ART outcomes over 10 years for patients 
with and without a history of mental illness for each 
treatment programme are shown in the appendix 
(pp 2, 5). Overall, mortality was higher in the Tygerberg 
tertiary care hospital than in the two primary care 
programmes. In all treatment programmes, the 
probability of death 10 years after ART initiation was 
higher in people with a history of mental illness than in 
those without.
In our univariate analysis, history of mental illness 
was associated with all-cause mortality (HR 3·05 
[95% CI 2·75–3·37]), mortality from natural causes 
(3·14 [2·81–3·51]), and mortality from unnatural causes 
(2·15 [1·29–3·56]; table 3, appendix p 3). Rates of excess 
all-cause mortality in patients with a history of mental 
illness and in those who initiated ART at WHO clinical 
stage 4 were similar (appendix p 3). In a multivariable 
analysis adjusted for age, sex, year of ART initiation, 
and treatment programme (model 1), history of mental 
illness was associated with all-cause mortality (aHR 2·98 
[95% CI 2·69–3·30]), mortality from natural causes 
(3·00 [2·69–3·36]), and mortality from un natural 
causes (2·10 [1·27–3·49]; table 3, appendix p 3). The 
associations between history of mental illness and 
mortality were marginally attenuated in a multi variable 
model adjusted for age, sex, year of ART initiation, 
treatment programme, and CD4 cell count and 
WHO clinical stage at ART initiation (model 2). With 
additional adjustment for retention in HIV care with or 
without VLS and LTFU (model 3), history of mental 
illness remained associated with all-cause mortality 
(aHR 2·73 [95% CI 2·46–3·02]) and mortality from 
natural causes (2·75 [2·46–3·08]; table 3, appendix p 3). 
The association between mental illness and all-cause 
See Online for appendix
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mortality (adjusted for age, sex, year of ART initiation, 
treatment programme, and CD4 cell count and WHO 
clinical stage at ART initiation) was greater (aHR 3·49 
[95% CI 3·09–3·94]) in sensitivity analysis, when we 
considered patients to be affected by mental illness 
(exposed) for 1 year after each mental health treatment 
(ie, dispensing of psychiatric medication or hospital 
admission for mental disorder) and as unexposed 
thereafter. Associations were gradually attenuated when 
the 1-year period was extended to 2, 3, 4, and 5 years 
(appendix p 4).
Figure 2 shows aHRs and 95% CIs for the transition 
rates of patients with a history of mental illness versus 
those without for each transition of the multistate model. 
Excess all-cause mortality in people with a history of 
mental illness occurred independently of HIV treatment 
outcomes. Associations between history of mental illness 
and all-cause mortality were greatest in patients retained 
in care with VLS (aHR 3·43 [95% CI 2·83–4·15]), 
followed by patients retained in care with NVL (2·74 
[2·32–3·24]), and smallest in those LTFU (2·12 
[1·78–2·53]). History of mental illness was also associated 
with increased rates of viral rebound (VLS to NVL, 1·50 
[1·32–1·69]) and increased rates of LTFU in people with 
VLS (1·19 [1·06–1·34]).
In subgroup analyses, associations between mortality, 
adverse HIV treatment outcomes (viral rebound and 
LTFU), and mental health treatment were stronger in 
patients who received mental health treatment during 
ART (appendix p 6) than in those who received mental 
health treatment before but not during ART (appendix 
p 7). Patients who received mental health treatment 
before but not during ART were at a higher risk of 
mortality but not a higher risk of LTFU or viral rebound 
than patients without a history of mental illness 
(appendix p 7). Patients who had been admitted to 
hospital for a mental disorder (appendix p 8) and patients 
who had never been admitted for a mental disorder but 
had received psychiatric medication (appendix p 9) had 
similar rates of excess all-cause mortality, viral rebound, 
and LTFU when compared with those without a history 
of mental illness. Among patients who received psy-
chiatric medications, those who received antipsy chotics 
had higher rates of excess all-cause mortality, viral 
rebound, and LTFU than those who received anti-
depressants or anxiolytics, when patients without a 
history of medication were the reference group (appendix 
p 10). Among patients who received psychiatric 
diagnoses, those diagnosed with substance use disorders 
had the greatest risk increase of unfavourable virological 
outcomes when compared with patients without a 
history of mental illness (appendix p 11). Notably, 
patients with substance use disorders had the lowest 
rate of achieving VLS and the highest rate of viral 
rebound. Increased rates of unfavourable virological 
outcomes were also seen in patients with affective or 
anxiety disorders, and rates of all-cause mortality were 
increased in patients with psychotic or anxiety disorders, 
compared with patients without a history of mental 
illness (appendix p 11).
No history of 
mental illness 
(n=55 737)
History of 
mental illness 
(n=2927)
Total (n=58 664)
Characteristics at ART initiation
Sex
Male 16 319 (29·3%) 892 (30·5%) 17 211 (29·3%)
Female 39 418 (70·7%) 2035 (69·5%) 41 453 (70·7%)
CD4 count, cells per µL
<100 10 579 (19·0%) 643 (22·0%) 11 222 (19·1%)
100–199 12 793 (23·0%) 678 (23·2%) 13 471 (23·0%)
200–349 12 884 (23·1%) 611 (20·9%) 13 495 (23·0%)
350–499 4289 (7·7%) 199 (6·8%) 4488 (7·7%)
≥500 2538 (4·6%) 123 (4·2%) 2661 (4·5%)
Missing 12 654 (22·7%) 673 (23·0%) 13 327 (22·7%)
Median (IQR) 186 (101–293) 171 (87–281) 186 (101–292)
WHO clinical stage
1 18 794 (33·7%) 666 (22·8%) 19 460 (33·2%)
2 10 163 (18·2%) 483 (16·5%) 10 646 (18·1%)
3 17 296 (31·0%) 959 (32·8%) 18 255 (31·1%)
4 7445 (13·4%) 664 (22·7%) 8109 (13·8%)
Missing 2039 (3·7%) 155 (5·3%) 2194 (3·7%)
Year of ART initiation
2004–07 9112 (16·3%) 443 (15·1%) 9555 (16·3%)
2008–11 17 250 (30·9%) 1027 (35·1%) 18 277 (31·2%)
2012–14 16 942 (30·4%) 919 (31·4%) 17 861 (30·4%)
2015–17 12 433 (22·3%) 538 (18·4%) 12 971 (22·1%)
Age at start of follow-up, years
15–24 6129 (11·0%) 233 (8·0%) 6362 (10·8%)
25–34 25 196 (45·2%) 1179 (40·3%) 26 375 (45·0%)
35–44 16 496 (29·6%) 910 (31·1%) 17 406 (29·7%)
45–54 6150 (11·0%) 444 (15·2%) 6594 (11·2%)
≥55 1766 (3·2%) 161 (5·5%) 1927 (3·3%)
Median (IQR) 33 (28–40) 35 (29–42) 33 (28–40)
HIV treatment outcome at end of follow-up
Retained in care 26 465 (47·5%) 1264 (43·2%) 27 729 (47·3%)
LTFU 17 946 (32·2%) 792 (27·1%) 18 738 (31·9%)
Transferred 7769 (13·9%) 418 (14·3%) 8187 (14·0%)
Died 3557 (6·4%) 453 (15·5%) 4010 (6·8%)
Natural cause* 2761 (77·6%) 378 (83·4%) 3139 (78·3%)
Unnatural cause* 199 (5·6%) 17 (3·8%) 216 (5·4%)
Unknown cause* 597 (16·8%) 58 (12·8%) 655 (16·3%)
HIV treatment outcome before death*
Retained in care with non-suppressed viral 
load
1352 (38·0%) 171 (37·7%) 1523 (38·0%)
Retained in care with viral load suppression 960 (27·0%) 131 (28·9%) 1091 (27·2%)
LTFU 1245 (35·0%) 151 (33·3%) 1396 (34·8%)
Data are n (%) unless otherwise stated. Percentages do not always add up to 100% due to rounding. Patients with 
documented pharmacological mental health treatment or mental health-related hospital admission were classified as 
having a history of mental illness. ART=antiretroviral therapy. LTFU=loss to follow-up. *Denominators for percentages 
are total deaths in that group.
Table 1: Patient characteristics by history of mental illness
Articles
e1331 www.thelancet.com/lancetgh   Vol 8   October 2020
Discussion
To our knowledge, this study is the first to quantify 
mortality associated with mental illness in HIV-positive 
people in South Africa, where the HIV-positive 
population accounts for 20% of all cases globally (2018 
UNAIDS estimate). This study showed substantial 
excess mortality and an increased rate of adverse HIV 
treatment outcomes in people with a history of mental 
illness versus those without. People with a history of 
mental illness had marginally higher rates of LTFU and 
viral rebound, around 3-times higher rates of mortality 
from all causes, and natural causes, and around 2-times 
higher rates of mortality from unnatural causes, than 
individuals with no history of mental illness. Excess 
mortality in people with mental illness was independent 
of reten tion in HIV care, VLS, and the stage of HIV 
disease progression at ART initiation. Excess death rates 
in patients with a history of mental illness and in those 
who initiated ART at WHO clinical stage 4 were similar.
The pattern of excess mortality observed in our study 
is consistent with previous studies of excess mortality 
associated with mental illness in HIV-positive popu lations. 
Two studies in the USA showed that risk of mortality was 
2–4 times higher in HIV-positive women with depression 
than in those without.7,8 A study in Tanzania found that in 
HIV-positive women, mortality risk was 2 times higher in 
women with symptoms of depression than in those 
without.10 A nationwide population-based cohort study 
in Denmark showed that mortality in people with 
schizophrenia and HIV was 3 times higher than mortality 
among people with HIV alone.9
Strong evidence shows that people with mental illness 
are less adherent to theraueptic regimens such as ART 
than people without mental illness.6 We expected that 
poor retention and adherence to ART would be an 
important driver of excess mortality in people living with 
Number of 
patients (%)
Any mental health treatment 2927 (100·0%)
Psychiatric medication 2565 (87·6%)
Antipsychotics (N05A) 1561 (60·9%)*
Anxiolytics (N05B) 815 (31·8%)*
Antidepressants (N06A) 1159 (45·2%)*
Other psychiatric medication (N05 or N06) 13 (0·5%)*†
Mental health-related hospital admission 923 (31·5%)
Hospitalised for substance use disorder 
(F10–F19) 
103 (11·2%)‡
Hospitalised for psychotic disorder (F20–F29) 182 (19·7%)‡
Hospitalised for affective disorder (F30–F39) 150 (16·3%)‡
Hospitalised for anxiety and related disorders 
(F40–F48) 
40 (4·3%)‡
Hospitalised for an unspecified (F99) or other 
mental disorder (F00–F09, F49–F98) 
276 (29·9%)‡
Hospitalised to psychiatric ward for unknown 
disorder 
356 (38·6%)‡
Patients with documented pharmacological mental health treatment or mental 
health-related hospital admission were classified as having a history of mental 
illness. Categories in the table are not mutually exclusive. Psychiatric medications 
were classified according to the Anatomical Therapeutic Chemical classification 
system and mental and substance use disorders according to the International 
Classification of Diseases, 10th Revision.*Percentages are out of those who 
received psychiatric medication. †Nine patients received hypnotics and sedatives 
(N05C) and four received psychostimulants (N06B). ‡Percentages are out of 
those admitted to hospital.
Table 2: Mental health treatment received by patients with a history of 
mental illness
Figure 1: Probability of HIV treatment outcomes and all-cause mortality 
during 10 years of ART for patients with a history of mental illness (A) and 
without a history of mental illness (B) 
Percentages represent the probability of being in each of the four states of the 
multistate model during 10 years on ART. ART=antiretroviral therapy.
0
10
20
30
40
50
60
70
80
90
100
Pr
ob
ab
ili
ty
 in
 p
at
ie
nt
s w
ith
 a
 h
ist
or
y o
f m
en
ta
l i
lln
es
s (
%
)
0 1 2 3 4 5 6 7 8 9 10
0
10
20
30
40
50
60
70
80
90
100
Pr
ob
ab
ili
ty
 in
 p
at
ie
nt
s w
ith
ou
t a
 h
ist
or
y o
f m
en
ta
l i
lln
es
s (
%
)
Time since ART initiation (years)
A
B
Retained in care with non-suppressed viral load
Retained in care with viral load suppression
Lost to follow-up
Died
For UNAIDS HIV prevalence 
data see https://aidsinfo.unaids.
org/
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HIV and mental illness. However, our study provides 
little support for this particular hypothesis. Excess 
mortality in people with mental illness occurred 
independently of HIV treatment outcomes. The largest 
mortality gap between patients with and without a history 
of mental illness was seen in patients retained on ART 
with VLS. As such, we believe that other underlying 
mechanisms are responsible for the excess mortality in 
people with mental illness.
One mechanism that contributes to excess mortality in 
people with mental disorders is excess mortality from 
unnatural causes. Although our study confirmed previous 
reports, which showed people with mental disorders to 
have an increased risk of unnatural death,16,17 we found 
that excess mortality from unnatural causes only 
accounted for a small proportion of the mortality gap in 
people with mental disorders. Consistent with previous 
studies, we found that most premature deaths in people 
with mental disorders were due to natural causes.2
Increased rates of physical illness and inadequate 
health care contribute to substantially higher than average 
rates of death from natural causes in people with mental 
disorders.18 Strong evidence suggests that some mental 
illnesses, such as depression and anxiety, are independent 
risk factors of physical illnesses including cardiovascular 
and metabolic diseases.19–22 Further reasons that might 
lead to increased incidence of physical illness in people 
with mental illness include side-effects of psychiatric 
medication (eg, weight gain and increased diabetogenic 
and cerebrovascular disease risk22), and high rates of 
adverse lifestyle behaviours (eg, poor diet, low physical 
activity, smoking, alcohol use, or drug use).18 Furthermore, 
disparities in health care might contribute to excess 
mortality in people with mental illness.18,23 Data from 
developed countries show that people with mental illness 
are less likely to receive physical examinations, screening, 
diagnostic tests, or the recommended standard of care for 
metabolic and cardiovascular diseases.18,22,23 Possible 
mechanisms under lying these disparities include 
differences in health-care seeking behaviour, structural 
barriers limiting access to health care for people with 
mental illness, misattribution of physical conditions as 
psychosomatic symptoms, implicit physician bias, and 
stigmatising attitudes of health-care providers towards 
people with mental illness.23,24
Although findings support a causal relationship between 
mental disorders and mortality, caution in interpreting 
these associations is warranted. Associations between 
mental disorders and mortality could also have a non-
causal origin and be the result of confounding. Physical 
comorbidity and socio economic status are important 
potential confounding factors. We adjusted for WHO 
clinical stage and CD4 cell count at ART initiation. These 
variables are generally accepted as good proxies for the 
most relevant physical ilnesses in people living with HIV 
(eg, pulmonary and extra pulmonary tuberculosis, and 
AIDS-defining cancers). However, we were limited by the 
data available for inclusion in our analyses and could not 
adjust for other potentially relevant comorbidities. 
Furthermore, we did not adjust for incident comorbidities 
after ART initiation because physical comorbidity is on the 
causal path from exposure (mental illness) to outcome 
(mortality).18–22 Adjustment for such intermediate variables 
would lead to overadjustment bias, resulting in substantial 
under estimation of excess mortality in mental illness.25 
Furthermore, we had no data on the socioeconomic status 
of patients and could not adjust for this potential 
confounder. However, we believe that in our study, socio-
economic status was not an important confounder because 
our study population had no major socio economic 
All-cause mortality,* 
HR (95% CI)
Mortality from 
natural cause,† 
HR (95% CI)
Mortality from unnatural 
cause,† HR (95% CI)
Univariable analyses 3·05 (2·75–3·37) 3·14 (2·81–3·51) 2·15 (1·29–3·56)
Multivariable analyses
Model 1 2·98 (2·69–3·30) 3·00 (2·69–3·36) 2·10 (1·27–3·49)
Model 2 2·76 (2·50–3·06) 2·78 (2·48–3·11) 2·05 (1·23–3·41)
Model 3 2·73 (2·46–3·02) 2·75 (2·46–3·08) 2·07 (1·24–3·44)
Model 1 adjusted for age, sex, year of ART initiation, and treatment programme; model 2 adjusted for all variables in 
model 1, and WHO clinical stage and CD4 cell count at ART initiation; model 3 adjusted for all variables in model 2 and 
HIV treatment status (retained with viral load suppression, retained with non-suppressed viral load, or loss to follow-
up). History of mental illness, age, and HIV treatment status were modeled as time-varying covariates. HR=hazard 
ratio. ART=antiretroviral therapy. *HRs for excess mortality in patients with a history of mental illness compared with 
patients without a history of mental illness. †Cause-specific HRs for excess mortality in patients with a history of 
mental illness compared with patients without a history of mental illness.
Table 3: HRs and cause-specific HRs for excess mortality in patients with a history of mental illness
Figure 2: aHRs comparing mortality and HIV treatment outcomes between 
patients with and without a history of mental illness
aHRs (95% CIs) are for the transition rates of patients with a history of mental 
illness versus those without for each transition of the multistate model. Patients 
without a history of mental illness were the reference group. Arrow width is 
proportional to the strength of the association. HRs were adjusted for age, 
sex, year of ART initiation, cumulative time with NVL, CD4 cell count and WHO 
clinical stage at ART initiation, and treatment programme. Values with 95% CIs 
that do not include 1 are shown in bold. aHR=adjusted hazard ratio. 
ART=antiretroviral therapy. LTFU=loss to follow-up. NVL=non-suppressed viral 
load. VLS=viral load suppression.
State 1: retained 
in care with NVL
State 2: retained 
in care with VLS
State 3: LTFU State 4: death1·50
(1·32–1·69)
1·11 
(0·99–1·25)
 2·74 
(2·32–3·24)
0·97 
(0·91–1·03)
1·19 
(1·06–1·34)
2·12 
(1·78–2·53)
3·43 
(2·83–4·15)
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differences that could explain the large mortality gap in 
people with mental disorders. Most people with and 
without mental disorders were enrolled in the public-
sector ART programmes at Gugulethu and Khayelitsha. 
These townships are among the poorest areas in Cape 
Town and people with higher soci oeconomic status are 
unlikely to access public-sector HIV care in these settings.
Although evidence for the effectiveness of strategies to 
improve survival in people with mental illness is scarce,18 
we believe that interventions addressing the multiple 
underlying drivers of excess mortality hold promise 
for closing the mortality gap between people with and 
without mental illness. Optimal dosing and screening 
for side-effects of psychiatric medication, screening and 
management of common chronic physical comorbidities, 
and interventions addressing adherence to therapeutic 
regimens, health equity, lifestyle behaviours, and stigma 
against people with mental illness could reduce the 
burden of physical illness among people with mental 
illness.18,23,26,27 Interventions should also include suicide 
prevention and ideally address social determinants of 
health.18,24 Our study also suggests that individuals who 
received antipsychotic medication are a highly vulnerable 
population requiring specific clinical attention.
The large sample size, long follow-up, multicohort 
design, inclusion of primary and tertiary care ART pro-
grammes, and data from multiple sources are important 
strengths of this study that add to the robustness and 
generalisability of our findings. The ascertainment of 
mortality by linking ART records to the South African 
National Population Register was a further strength that 
enabled us to assess excess mortality in people with mental 
illness among people who were not retained in HIV care.
Our results should be considered in view of several 
limitations. We classified the mental health status of 
patients on the basis of routinely collected records of 
mental health treatments. We used hospital admissions 
for mental health disorders and receipt of prescrip-
tions for psychiatric medications as the best available 
proxies for mental illness. As such, patients receiving 
non-pharma co logical outpatient interventions such as 
psycho therapy might have been overlooked, and patients 
who received psychiatric medications for indications not 
related to mental health might have been misclassified. 
Globally, most people living with mental illness do 
not have access to mental health treatment.28 In our 
study, people who were affected by mental disorders 
but remained untreated would have been misclassified 
as having no history of mental illness. Misclassification 
of untreated people with mental illness would have 
led to bias towards the null hypothesis. Therefore, our 
study might underestimate associations between mental 
illness, mortality, and adverse HIV treatment outcomes. 
People with mild forms of mental disorders might be 
less likely to be diagnosed and treated, and thus people 
with severe mental illness might be over-represented in 
our sample. Our study might therefore overestimate 
associations between mental illness, mortality, and 
adverse HIV treatment outcomes. ICD-10 diagnoses 
were only available from hospital discharge summaries 
and only for a small percentage of the individuals with 
mental illness. Our subgroup analysis of associations 
between particular types of disorders and HIV treatment 
outcomes has to be interpreted with caution as only the 
more severe cases that required hospitalisation were 
likely to be included in this analysis. Throughout our 
analyses, we could not adjust HIV programme data for 
undocumented transfers and we did not consider 
intermittent treatment interruptions in patients who 
returned to care as LTFU periods.29
Although our results need to be interpreted in the 
context of some limitations, our study is one of the few to 
assess associations between mental illness, mortality, and 
other HIV-related outcomes. Mental illness was inde-
pendently associated with decreased retention on ART, 
decreased VLS, and increased mortality from natural and 
unnatural causes. These findings suggest that excess 
mortality in people with mental illness cannot be solely 
attributed to the negative effect of mental illness on HIV 
treatment. Interventions to reduce excess mortality in 
people with mental illness should go beyond support for 
treatment adherence and address the complex physical 
and mental health-care needs of people living with HIV 
and mental illness.
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